Conditions: Alzheimer's Disease
Keywords: Randomized Safety Study Adaptive Double Blind
Allocation: RANDOMIZED | Intervention model: 
Enrollment: 88
Healthy volunteers: no

Brief summary:
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo. Each patient's participation will last approximately 41 weeks.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None

Interventions: intervention 1: AAB-003 (PF-05236812) intervention 2: AAB-003 (PF-05236812) intervention 3: AAB-003 (PF-05236812) intervention 4: AAB-003 (PF-05236812) intervention 5: AAB-003 (PF-05236812) intervention 6: Placebo
Intervention descriptions: intervention 1: 0.5 mg/kg AAB-003, IV intervention 2: 1 mg/kg AAB-003, IV intervention 3: 2 mg/kg AAB-003, IV intervention 4: 4 mg/kg AAB-003, IV intervention 5: 8 mg/kg AAB-003, IV intervention 6: Placebo, IV

Protocol document: